Descrizione

Risk factors and clinical heterogeneity of mild cognitive impairment, with discussion of how different evaluation methods and population characteristics affect MCI prevalence estimates.

Figure 6

Diagram

Source Paper

Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®).

Pharmaceuticals (Basel, Switzerland) (2021)

PMID: 33915701

DOI: 10.3390/ph14040305

Cite This Figure

![Figure 6: Risk factors and clinical heterogeneity of mild cognitive impairment, with discussion of how different evaluation methods and population characteristics affect MCI prevalence estimates.]()

> Source: Carlo Tomino et al. "Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®." *Pharmaceuticals (Basel, Switzerland)*, 2021. PMID: [33915701](https://pubmed.ncbi.nlm.nih.gov/33915701/)

<figure>
  <img src="" alt="Risk factors and clinical heterogeneity of mild cognitive impairment, with discussion of how different evaluation methods and population characteristics affect MCI prevalence estimates." />
  <figcaption>Figure 6. Risk factors and clinical heterogeneity of mild cognitive impairment, with discussion of how different evaluation methods and population characteristics affect MCI prevalence estimates.<br>  Source: Carlo Tomino et al. "Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33915701/">33915701</a></figcaption>
</figure>

Evidenze correlate

Ginkgo biloba per Age-Related Cognitive Decline

Grado C · 40 studi